PE20191144A1 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- PE20191144A1 PE20191144A1 PE2019001014A PE2019001014A PE20191144A1 PE 20191144 A1 PE20191144 A1 PE 20191144A1 PE 2019001014 A PE2019001014 A PE 2019001014A PE 2019001014 A PE2019001014 A PE 2019001014A PE 20191144 A1 PE20191144 A1 PE 20191144A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hexafluoropropan
- trifluoromethyl
- cr6r7
- oxobutyl
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title 1
- 101710116393 Monoglyceride lipase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- -1 2 - ((4 - (((1,1,1,3,3,3-hexafluoropropan-2-yl) oxy) carbonyl) piperazin-1-yl) methyl) -5- (trifluoromethyl) phenoxy Chemical group 0.000 abstract 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 abstract 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000002621 endocannabinoid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423099P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191144A1 true PE20191144A1 (es) | 2019-09-02 |
Family
ID=62106678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001014A PE20191144A1 (es) | 2016-11-16 | 2017-11-15 | Inhibidores de magl |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10093635B2 (enExample) |
| EP (1) | EP3541821A4 (enExample) |
| JP (1) | JP7042547B2 (enExample) |
| KR (1) | KR20190077544A (enExample) |
| CN (1) | CN110267963B (enExample) |
| AR (1) | AR110089A1 (enExample) |
| AU (1) | AU2017361251B2 (enExample) |
| BR (1) | BR112019009994A2 (enExample) |
| CA (1) | CA3043615A1 (enExample) |
| CL (1) | CL2019001339A1 (enExample) |
| CO (1) | CO2019005059A2 (enExample) |
| CR (1) | CR20190241A (enExample) |
| DO (1) | DOP2019000122A (enExample) |
| EA (1) | EA038090B1 (enExample) |
| EC (1) | ECSP19035077A (enExample) |
| GE (2) | GEP20237470B (enExample) |
| IL (1) | IL266523B (enExample) |
| JO (1) | JOP20190106A1 (enExample) |
| MA (1) | MA46857A (enExample) |
| MX (1) | MX391117B (enExample) |
| NI (1) | NI201900051A (enExample) |
| PE (1) | PE20191144A1 (enExample) |
| PH (1) | PH12019501097A1 (enExample) |
| RU (1) | RU2754536C1 (enExample) |
| TN (1) | TN2019000153A1 (enExample) |
| TW (1) | TWI756299B (enExample) |
| UA (1) | UA124542C2 (enExample) |
| WO (1) | WO2018093947A1 (enExample) |
| ZA (1) | ZA201903100B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000198T1 (it) | 2012-01-06 | 2020-07-08 | Scripps Research Inst | Composti di carbammato e metodi di produzione e di utilizzo degli stessi |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| CN110290791A (zh) | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| SG11202011228TA (en) * | 2018-05-15 | 2020-12-30 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
| AU2020383502A1 (en) * | 2019-11-15 | 2022-06-30 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| IT202000007150A1 (it) * | 2020-04-03 | 2021-10-03 | Univ Pisa | Inibitori di monoacilglicerolo lipasi (magl) |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023130023A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| EP0619804B1 (en) | 1991-11-27 | 1996-05-22 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| EP0736047B1 (en) | 1993-12-22 | 1998-03-04 | Shell Internationale Researchmaatschappij B.V. | Process for preparing carbamates |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| AU7856600A (en) | 1999-10-04 | 2001-05-10 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| KR20070026382A (ko) | 2004-02-18 | 2007-03-08 | 아스트라제네카 아베 | 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도 |
| EP1831218A2 (en) | 2004-12-23 | 2007-09-12 | F.Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| ME02929B (me) | 2004-12-30 | 2018-04-20 | Janssen Pharmaceutica Nv | DERIVATIVI FENILAMIDA 4-(BENZIL)-PIPERAZIN-1-KARBOKSILNE KISELINE l SLIĆNA JEDINJENJA KAO MODULATORI HIDROLAZE AMIDA MASNIH KISELINA (FAAH) ZA LEĆENJE ANKSIOZNOSTI, BOLA l OSTALIH STANJA |
| EP1948630A2 (en) * | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| CN101711154A (zh) | 2007-02-26 | 2010-05-19 | 科森生物科学公司 | 氨基甲酸酯化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| CA2743861A1 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| RU2011147181A (ru) * | 2009-04-22 | 2013-05-27 | Янссен Фармацевтика Нв | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| ES2433235T3 (es) | 2009-11-03 | 2013-12-10 | Bayer Intellectual Property Gmbh | Fluorouretanos como aditivos en una formulación de fotopolímero |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SMT202000198T1 (it) * | 2012-01-06 | 2020-07-08 | Scripps Research Inst | Composti di carbammato e metodi di produzione e di utilizzo degli stessi |
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
| JP2014005245A (ja) * | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016014975A2 (en) * | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10899737B2 (en) * | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-06-16 JO JOP/2019/0106A patent/JOP20190106A1/ar unknown
- 2017-11-15 MX MX2019005776A patent/MX391117B/es unknown
- 2017-11-15 KR KR1020197016924A patent/KR20190077544A/ko not_active Abandoned
- 2017-11-15 EP EP17871753.4A patent/EP3541821A4/en not_active Withdrawn
- 2017-11-15 UA UAA201905620A patent/UA124542C2/uk unknown
- 2017-11-15 CR CR20190241A patent/CR20190241A/es unknown
- 2017-11-15 GE GEAP201715088A patent/GEP20237470B/en unknown
- 2017-11-15 MA MA046857A patent/MA46857A/fr unknown
- 2017-11-15 TN TNP/2019/000153A patent/TN2019000153A1/en unknown
- 2017-11-15 BR BR112019009994A patent/BR112019009994A2/pt not_active IP Right Cessation
- 2017-11-15 GE GEAP202215088A patent/GEAP202215088A/en unknown
- 2017-11-15 JP JP2019523587A patent/JP7042547B2/ja not_active Expired - Fee Related
- 2017-11-15 RU RU2019116512A patent/RU2754536C1/ru active
- 2017-11-15 US US15/814,322 patent/US10093635B2/en active Active
- 2017-11-15 IL IL266523A patent/IL266523B/en unknown
- 2017-11-15 AR ARP170103184A patent/AR110089A1/es not_active Application Discontinuation
- 2017-11-15 CA CA3043615A patent/CA3043615A1/en active Pending
- 2017-11-15 AU AU2017361251A patent/AU2017361251B2/en not_active Ceased
- 2017-11-15 WO PCT/US2017/061868 patent/WO2018093947A1/en not_active Ceased
- 2017-11-15 EA EA201991073A patent/EA038090B1/ru unknown
- 2017-11-15 PE PE2019001014A patent/PE20191144A1/es unknown
- 2017-11-15 CN CN201780083663.6A patent/CN110267963B/zh not_active Expired - Fee Related
- 2017-11-16 TW TW106139775A patent/TWI756299B/zh not_active IP Right Cessation
-
2019
- 2019-05-16 CO CONC2019/0005059A patent/CO2019005059A2/es unknown
- 2019-05-16 PH PH12019501097A patent/PH12019501097A1/en unknown
- 2019-05-16 NI NI201900051A patent/NI201900051A/es unknown
- 2019-05-16 DO DO2019000122A patent/DOP2019000122A/es unknown
- 2019-05-16 CL CL2019001339A patent/CL2019001339A1/es unknown
- 2019-05-16 EC ECSENADI201935077A patent/ECSP19035077A/es unknown
- 2019-05-17 ZA ZA201903100A patent/ZA201903100B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191144A1 (es) | Inhibidores de magl | |
| PE20191146A1 (es) | Inhibidores de magl | |
| PE20211385A1 (es) | Inhibidores de magl | |
| PE20121280A1 (es) | Derivados de (tio)morfolina como moduladores de s1p | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20170947A1 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| PE20210397A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer | |
| PE20180175A1 (es) | Nuevos derivados de imidazolilmetilo 5-sustituidos | |
| PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
| PE20161247A1 (es) | Benzamidas sustituidas y metodos para usarlas | |
| PE20130385A1 (es) | Derivados del acido naft-2-ilacetico para tratar el sida | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| PE20090815A1 (es) | Compuesto de amida | |
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| EA201890109A1 (ru) | Новые алкинилзамещенные 3-фенилпирролидин-2,4-дионы и их применение в качестве гербицидов | |
| PE20091816A1 (es) | Inhibidores de bace | |
| PE20090757A1 (es) | Formulaciones que contienen triazinonas y hierro | |
| UY36750A (es) | Compuesto heterocíclico | |
| PE20170326A1 (es) | Herbicidas de piridazinona | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
| DOP2014000285A (es) | Composicion herbicida que tiene actividad herbicida mejorada | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| PE20080136A1 (es) | Arilsulfonamidas sustituidas como agentes antivirales |